Literature DB >> 20194287

Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child.

Giorgos Chouliaras1, Vana Spoulou, Mark Quinlivan, Judith Breuer, Maria Theodoridou.   

Abstract

Varicella-zoster virus vaccine has diminished the consequences of chicken pox in terms of health and economical burden. The increasing number of doses administered worldwide has revealed rare but important adverse effects that had not occurred during clinical trials. We report here the case of an immunocompetent 3(1/2)-year-old girl who developed encephalitis and herpes zoster opthalmicus 20 months after her immunization with varicella-zoster virus vaccine. Molecular analysis confirmed the vaccine strain as the causative agent. After an intravenous course with acyclovir, the child made a full recovery with no neurologic sequelae.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20194287     DOI： 10.1542/peds.2009-2633

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


  17 in total

1.  Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells.

Authors:  Jenna Christensen; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  A Toddler With Rash, Encephalopathy, and Hemolytic Anemia.

Authors:  Christiana Smith; Cullen Dutmer; D Scott Schmid; Megan K Dishop; William J Bellini; Erwin W Gelfand; Edwin J Asturias
Journal:  J Pediatric Infect Dis Soc       Date:  2015-05-28       Impact factor: 3.164

3.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

4.  Vaccine Oka Varicella Meningitis in Two Adolescents.

Authors:  Whitney E Harrington; Sayonara Mató; Lauri Burroughs; Paul A Carpenter; Anne Gershon; D Scott Schmid; Janet A Englund
Journal:  Pediatrics       Date:  2019-12       Impact factor: 7.124

5.  Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine.

Authors:  Barbara A Pahud; Carol A Glaser; Cornelia L Dekker; Ann M Arvin; D Scott Schmid
Journal:  J Infect Dis       Date:  2010-12-21       Impact factor: 5.226

6.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

7.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

Review 8.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 9.  Neurovirulence of varicella and the live attenuated varicella vaccine virus.

Authors:  Corey Horien; Charles Grose
Journal:  Semin Pediatr Neurol       Date:  2012-09       Impact factor: 1.636

10.  Herpes zoster ophthalmicus in an otherwise healthy 2-year-old child.

Authors:  Marijn Soeteman; Rick P P Willems; Jamiu O Busari
Journal:  BMJ Case Rep       Date:  2012-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.